Cardio Diagnostics Holdings, Inc. (CDIO) 股票分析

公司概述

Cardio Diagnostics Holdings, Inc. is a biotechnology enterprise dedicated to developing and commercializing epigenetics-based clinical tests designed to assess risks associated with cardiovascular disease. By offering the Epi+Gen CHD test, the company targets symptomatic coronary heart disease events, including heart attacks, through a three-year clinical blood test framework. The firm operates within the healthcare sector, specifically the biotechnology industry, where innovation in diagnostic tools is critical for advancing patient outcomes. With a market capitalization of $5.36M, annual revenue of $14,825, and an employee base of 15, the company maintains a very small operational scale. These financial figures indicate that the entity is a micro-cap biotechnology firm with minimal revenue generation relative to its market valuation, suggesting it is in an early-stage development or commercialization phase where capital allocation focuses heavily on product research rather than established sales volume.

财务健康

The company reported trailing twelve-month revenue of $14,825, yet recorded a net income loss of $-6,498,167, revealing a significant gap between top-line sales and profitability driven by high operating costs or research expenditures. EBITDA for the period stands at $-6,085,950, further highlighting the substantial cash burn required to sustain operations. Free cash flow is negative at $-3,809,743, which implies that the company is currently burning cash rather than generating liquidity, thereby limiting its financial flexibility to fund growth without external financing. Margin analysis shows a gross margin of 100.0%, indicating no cost of goods sold relative to revenue, while the operating margin is -41159.6% and profit margin is 0.0%, reflecting severe losses relative to sales due to high overheads or one-time charges. The balance sheet holds $5.11M in cash against $695,619 in debt, resulting in a debt-to-equity ratio of 9.97, which suggests a highly leveraged capital structure despite the cash reserve. However, the current ratio of 9.79 indicates strong short-term liquidity, as current assets significantly exceed current liabilities, providing a buffer against immediate obligations. Return on equity is -78.6% and return on assets is -44.1%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.

估值评估

Valuation multiples for the company include a trailing P/E ratio of N/A and a forward P/E of -7.24, where the negative forward P/E implies that future earnings are projected to remain negative, negating traditional earnings-based valuation models. The price-to-book ratio is 0.47, indicating that the market values the company at less than its book value, which often occurs when investors discount assets in a biotech firm that may not yet be monetized. Alternative metrics such as the price-to-sales ratio of 361.32 and EV/EBITDA of -0.15 suggest that the market is pricing the stock based on speculative growth potential rather than current financial performance or cash flow generation. The stock's price action over the past year has ranged between a 52-week high of $17.40 and a 52-week low of $0.97, meaning the current price sits significantly below the recent peak but remains above the historical floor. The beta of 2.66 indicates that the stock's price volatility is more than twice that of the broader market, exposing investors to heightened risk during market fluctuations.

Growth & Income

Revenue growth year-over-year is negative at -21.2%, while earnings growth is N/A due to the lack of prior positive earnings; this implies that the company is contracting in sales rather than expanding its market share. As a non-dividend payer, the company offers a dividend yield of N/A and a payout ratio of 0.0%, meaning no portion of earnings is distributed to shareholders, and all resources are theoretically retained for operational continuity. Consequently, the company reinvests its limited earnings, or rather its capital reserves, into growth initiatives rather than paying dividends, which is typical for pre-profitable biotechnology firms. Overall, the growth and income profile is characterized by declining revenue, negative earnings, and zero dividend distribution, reflecting a high-risk, high-volatility investment characteristic of early-stage healthcare biotech companies.